Having met the primary endpoint in its OPTIMIZE-1 phase II trial with mitazalimab in pancreatic cancer,
Read the interview with Sumeet Ambarkhane at biostock.se:
https://www.biostock.se/en/2024/02/alligator-prepares-for-phase-iii-with-cd40-agonist/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/
https://news.cision.com/alligator-bioscience/r/biostock--alligator-prepares-for-phase-iii-with-cd40-agonist,c3929807
(c) 2024 Cision. All rights reserved., source